Previous studies have shown clinical benefits, but also an increased cost to treat patients with symptomatic severe aortic stenosis receiving transcatheter valve replacement (TAVR). There is little consensus regarding the cost-effectiveness for transcatheter versus surgical replacement. The present study was aimed to quantify the quality of life, adjusted survival for quality of life, resource utilization,…
CoreValve US Pivotal Trial: 2-year results of the self-expanding valve on inoperable patients
This study evaluated the safety and effectiveness of the CoreValve transcatheter valve replacement in patients with severe aortic stenosis with extreme risk for surgery. The primary end point was a composite of all-cause mortality and stroke at 24 months. The rate of death from any cause or cerebrovascular accident at 24 months was 38% for…
PARTNER cohort B: 5-year results of a balloon-expandable valve on inoperable patients
This study included 358 patients considered inoperable, randomized to TAVR with expandable balloon valve versus conservative treatment. The 5-year end points included all-cause mortality, cardiac mortality, re-hospitalization, and stroke. At 5 years, mortality from all causes was lower in TAVR group versus conservative treatment group (71.8% versus 93.6%, P <0.0001). By dividing patients by STS…
CLEAN-TAVI: transcatheter aortic valve replacement with cerebral protection
The stroke is a leading complication of post transcatheter aortic valve implantation increasing up to 3 times the mortality of these patients. In the works performed neuroimaging new post, TAVR defects were observed in two-thirds of patients and this increases the risk of post clinical stroke. There is a missing data in the literature of…
ISAR-CLOSURE: FemoSeal and ExoSeal versus manual compression after femoral access
Previous studies with vascular closure devices showed shorter hemostasis and less downtime post-procedure. This study compared the safety and efficacy of two vascular closure devices (FemoSeal and ExoSeal) versus manual compression. The work included 4524 patients undergoing diagnostic coronary angiography using a 6 Fr introducer, randomized 1: 1: 1 to FemoSeal, ExoSeal or manual compression.…
